NASHVILLE, Tenn., Dec. 1, 2023
/PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"),
a publicly traded special purpose acquisition company, announced
today that it has signed a non-binding letter of intent ("LOI") for
a proposed business combination (the "Business Combination") with a
precision medicine company that offers genomic diagnostic tests in
clinical genomics, oncology, human microbiome and reproductive
genomics, as well as a digital nutrition-based DNA and gut
microbiome wellness service that promotes wellbeing and prevents
disease ("Target"), that would result in a public listing of the
combined company upon completion of the proposed Business
Combination. The Target is focused on the Spanish speaking
global population through its diagnostic and wellness business
divisions, providing both health practitioners and consumers with
genomic data-driven insights with the purpose of improving people's
quality of life, positively impacting their whole life arc. The
Target extracts blood, tissue, saliva and/or microbiome samples,
and analyzes and processes the biological data through a wholly
owned laboratory that possess next generation sequencing technology
and provides support through expert analysis via either medical
geneticists or nutrigenetic certified nutritionists.
The Company expects to announce additional details regarding the
Business Combination when a definitive business combination
agreement is executed.
About APX Acquisition Corp. I
The Company is a
special purpose acquisition company, led by serial SPAC sponsor
Kyle Bransfield, formed for the
purpose of effecting a business combination with one or more
businesses or entities. While the Company may pursue an initial
business combination in any industry, The Company intends to focus
its search on companies in Spanish-speaking Latin American
countries or companies outside of Latin
America that provide goods and services to Spanish-speaking
markets.
About Bioceres Group
Bioceres Group is an advanced
life sciences platform, dedicated to the preservation of the planet
and improvement of human life. The Group promotes and
develops disruptive technologies that are strongly aligned with
sustainability and human wellbeing goals, across four verticals:
carbon neutrality, biomaterials, functional foods, and health and
wellness.
Forward-Looking Statements
This press release includes, and oral statements made from time
to time by representatives of the Company may include,
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Statements regarding
possible business combinations and the financing thereof, and
related matters, as well as all other statements other than
statements of historical fact included in this press release are
forward-looking statements. When used in this press release, words
such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "plan," "possible,"
"potential," "predict," "project," "should," "would" and similar
expressions, as they relate to the Company or the Company's
management team, identify forward-looking statements. Such
forward-looking statements are based on the beliefs of the
Company's management, as well as assumptions made by, and
information currently available to, the Company's management.
Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors
detailed in the Company's filings with the SEC. All subsequent
written or oral forward-looking statements attributable to the
Company or persons acting on the Company's behalf are qualified in
their entirety by this paragraph. Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company, including those set forth in the "Risk
Factors" section of the Company's registration statement and final
prospectus relating to the Company's initial public offering filed
with the SEC. Copies are available on the SEC's website at
www.sec.gov. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by applicable law.
Contacts:
APx Acquisition Corp. I:
Kyle Bransfield
Chief Executive Officer
kyle.bransfield@unionacquisitiongroup.com
Bioceres Group:
Gabino Rebaglati
Gabion.rebagliati@bioceresgroup.com
Brenda Hirigoyen
bhirigoyen@biocerescrops.com
View original
content:https://www.prnewswire.com/news-releases/apx-acquisition-corp-i--bioceres-group-announce-letter-of-intent-for-a-business-combination-with-a-precision-medicine-diagnostic-and-wellness-services-company-302003770.html
SOURCE APx Acquisition Corp I
